NCT01145352

Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]

Enbrel-JIA Use Results Survey [All-Case Surveillance]

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 113 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 5 Years – 16 Years
• Healthy volunteers: Not accepted

Summary

This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events 2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.

Detailed description

All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).

Conditions

• Juvenile Idiopathic Arthritis

Interventions

Type	Name	Description
DRUG	Etanercept (genetical recombination)	All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).

Timeline

• Start date: 2009-07-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2010-06-16
• Last updated: 2014-09-04
• Results posted: 2014-09-04

Locations

1 site across 1 country: Japan